Regal Investment Advisors LLC Has $2.25 Million Holdings in United Therapeutics Co. (UTHR)

Regal Investment Advisors LLC boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 17.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,554 shares of the biotechnology company’s stock after acquiring an additional 2,596 shares during the quarter. Regal Investment Advisors LLC’s holdings in United Therapeutics were worth $2,245,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. WINTON GROUP Ltd raised its position in shares of United Therapeutics by 175.9% during the 3rd quarter. WINTON GROUP Ltd now owns 92,259 shares of the biotechnology company’s stock valued at $11,798,000 after acquiring an additional 58,814 shares in the last quarter. Unison Advisors LLC acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at approximately $224,000. HL Financial Services LLC raised its position in shares of United Therapeutics by 22.6% during the 3rd quarter. HL Financial Services LLC now owns 3,324 shares of the biotechnology company’s stock valued at $425,000 after acquiring an additional 613 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at approximately $2,816,000. Finally, Robeco Institutional Asset Management B.V. raised its position in shares of United Therapeutics by 25.0% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 325,317 shares of the biotechnology company’s stock valued at $41,604,000 after acquiring an additional 65,049 shares in the last quarter. Hedge funds and other institutional investors own 95.71% of the company’s stock.

In other news, Director Christopher Causey sold 810 shares of the stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $118.00, for a total value of $95,580.00. Following the completion of the transaction, the director now owns 3,925 shares of the company’s stock, valued at $463,150. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard Giltner sold 3,240 shares of the stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total value of $419,191.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,860 shares of company stock valued at $611,161. 8.20% of the stock is owned by company insiders.

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a research report on Thursday, August 2nd. Credit Suisse Group dropped their price target on United Therapeutics from $106.00 to $103.00 and set an “underperform” rating on the stock in a research report on Thursday, November 1st. JPMorgan Chase & Co. upped their price target on United Therapeutics from $118.00 to $126.00 and gave the company a “neutral” rating in a research report on Friday, November 2nd. Cowen set a $106.00 price target on United Therapeutics and gave the company a “hold” rating in a research report on Wednesday, October 31st. Finally, Zacks Investment Research lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Sunday, July 15th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $136.25.

Shares of UTHR opened at $116.15 on Thursday. The firm has a market cap of $5.10 billion, a P/E ratio of 10.67, a P/E/G ratio of 27.09 and a beta of 1.23. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a 12 month low of $100.57 and a 12 month high of $152.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 EPS for the quarter, missing the Zacks’ consensus estimate of $3.23 by ($0.81). The company had revenue of $412.70 million for the quarter, compared to the consensus estimate of $378.22 million. United Therapeutics had a return on equity of 25.24% and a net margin of 31.73%. United Therapeutics’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.69 earnings per share. On average, equities analysts forecast that United Therapeutics Co. will post 14.39 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://sportsperspectives.com/2018/11/08/regal-investment-advisors-llc-has-2-25-million-holdings-in-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading: What are the Different Types of Leveraged Buyouts?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply